PMID- 15671554
OWN - NLM
STAT- MEDLINE
DCOM- 20050628
LR  - 20171116
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 11
IP  - 1
DP  - 2005 Jan 1
TI  - Prognostic significance of Jab1 expression in laryngeal squamous cell carcinomas.
PG  - 259-66
AB  - PURPOSE: Jun activation domain-binding protein 1 (Jab1) is known as a coactivator 
      of AP1 transcription factor, which contributes to tumor progression by degrading 
      the p27kip1 protein. The purpose of this study is to investigate whether Jab1 
      expression is correlated with p27kip1 level and cell proliferation, as well as 
      whether Jab1 expression is associated with clinicopathologic variables and 
      prognosis of laryngeal squamous cell carcinoma (LSCC). EXPERIMENTAL DESIGN: 
      Immunohistochemical and/or Western blot analysis was done in HEp-2 cells and 102 
      cases of LSCCs. RESULTS: Jab1 expression was negatively associated with p27kip1 
      expression and was positively associated with cell proliferation both in HEp-2 
      cells and LSCCs. Jab1 overexpression was detected in 51% LSCCs and was 
      significantly associated with unfavorable clinicopathologic variables. Survival 
      analysis revealed that Jab1 overexpression is significantly associated with short 
      disease-free and overall survival (P = 0.0036 and P = 0.0001, respectively). When 
      Jab1 and p27kip1 are combined, patients with Jab1(+)/p27kip1(-) revealed poor 
      disease-free and overall survival (P= 0.0008 and P < 0.0001, respectively). When 
      Jab1 expression and lymph node status are combined, patients with Jab1(+)/lymph 
      node(+) revealed poorer disease-free andoverall survival than others (P < 0.0001 
      and P < 0.0001, respectively). Furthermore, patients with the phenotype of 
      Jab1(+)/p27kip1(-)/lymph node(+) revealed the worst disease-free and overall 
      survival (P < 0.0001 and P < 0.0001, respectively). Multivariate analysis 
      revealed that Jab1 protein is an independent prognostic indicator for overall 
      survival. CONCLUSIONS: These findings suggested that Jab1 protein may contribute 
      to the tumor progression and represent a novel prognostic indicator for LSCCs.
FAU - Dong, Youyi
AU  - Dong Y
AD  - Department of Cell Physiology, Faculty of Medicine, Kagawa University, Kagawa, 
      Japan.
FAU - Sui, Li
AU  - Sui L
FAU - Watanabe, Yasuo
AU  - Watanabe Y
FAU - Yamaguchi, Fuminori
AU  - Yamaguchi F
FAU - Hatano, Naoya
AU  - Hatano N
FAU - Tokuda, Masaaki
AU  - Tokuda M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Cdkn1b protein, mouse)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Transcription Factors)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 147604-94-2 (Cyclin-Dependent Kinase Inhibitor p27)
RN  - EC 3.4.- (Peptide Hydrolases)
RN  - EC 3.4.-.- (COPS5 protein, human)
RN  - EC 3.4.-.- (Cops5 protein, mouse)
RN  - EC 3.4.19.12 (COP9 Signalosome Complex)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Blotting, Western
MH  - COP9 Signalosome Complex
MH  - Carcinoma, Squamous Cell/diagnosis/*metabolism/*mortality
MH  - Cell Cycle Proteins/biosynthesis
MH  - Cell Line, Tumor
MH  - Cell Nucleus/metabolism
MH  - Cell Proliferation
MH  - Cyclin-Dependent Kinase Inhibitor p27
MH  - DNA-Binding Proteins/*biosynthesis
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - Intracellular Signaling Peptides and Proteins
MH  - Laryngeal Neoplasms/diagnosis/*metabolism/*mortality
MH  - Lymphatic Metastasis
MH  - Male
MH  - Mice
MH  - Microscopy, Fluorescence
MH  - Middle Aged
MH  - Models, Statistical
MH  - Multivariate Analysis
MH  - NIH 3T3 Cells
MH  - Peptide Hydrolases/*biosynthesis
MH  - Phenotype
MH  - *Prognosis
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Time Factors
MH  - Transcription Factors/*biosynthesis
MH  - Treatment Outcome
MH  - Tumor Suppressor Proteins/biosynthesis
EDAT- 2005/01/27 09:00
MHDA- 2005/06/29 09:00
CRDT- 2005/01/27 09:00
PHST- 2005/01/27 09:00 [pubmed]
PHST- 2005/06/29 09:00 [medline]
PHST- 2005/01/27 09:00 [entrez]
AID - 11/1/259 [pii]
PST - ppublish
SO  - Clin Cancer Res. 2005 Jan 1;11(1):259-66.